Teva Pharmaceutical Industries reported Q2 results on July 29, and with the stock recovering to $31.67 — up 1.9% on the day and roughly 1% on the week — the immediate market reaction has been mildly constructive, even as the shares remain about 4% below where they traded a month ago.
The most notable development this week came from Piper Sandler's David Amsellem, who raised his price target to $44 from $42 on July 28 while maintaining an Overweight rating. That move is consistent with a broader analyst trend that has been firmly one-directional: every recent change in the data has been a raise, not a cut. JPMorgan, UBS, Goldman Sachs, Truist, and BofA all lifted targets following the Q1 print in late April, and the consensus mean now sits at $41 — roughly 29% above the current price. The gap between the Street's view and where the stock trades is the defining tension in TEVA right now. The bull case rests on the diversified generics and biosimilars portfolio, the neurology pipeline including the D1 antagonist program for Tourette syndrome, and ongoing debt reduction. Bears point to intensifying US generics competition, the ProAir HFA patent ruling, and limited balance sheet flexibility for large deals. With four Outperform-category ratings and a Buy consensus, the Street is leaning decisively in one direction — but the market has not yet followed.
Positioning data reinforces the picture of a stock that generates little heat from short sellers. Short interest has eased about 3.4% over the past week to roughly 31.4 million shares, continuing a decline from a mid-July peak near 34.4 million. Borrow costs are negligible at 0.42%, down around 16% over the past month. Availability has expanded sharply — now at over 2,400% of short interest, the loosest reading in several weeks and well above the 52-week floor of 758%. There is no pressure on the lending market, no crowding in bearish positions, and no sign of a squeeze. The options market is equally quiet: the put/call ratio of 0.37 matches its 20-day average almost exactly, with a z-score near zero. Defensive hedging is close to its lightest level of the past year relative to the 52-week high PCR of 0.76.
Institutional ownership adds useful texture. WCM Investment Management stands out — the firm reported holding 40.8 million shares as of June 30, having added 26.8 million shares in the most recent filing period, a move that makes it one of the largest recent buyers in the register. BlackRock, Capital Research, and FMR also added to positions over the same window. On the other side, Rubric Capital trimmed by 6.1 million shares. The overall picture is one of active accumulation by a handful of managers, rather than broad-based rotation.
The short score of 38.5 has drifted slightly lower over the past week from a recent high of 39.7, consistent with the easing in short interest. Valuation multiples have moved modestly: the P/E of 11.8x is down about 0.8x over the past month even as the stock has recovered intraday, while EV/EBITDA of 9.8x has edged higher. The factor score picture is mixed — the dividend rank of 72 and EV/EBIT rank of 68 are relative positives, while EPS surprise at the 27th percentile and forward EPS growth at the 26th reflect the earnings quality concerns the bears continue to press.
What to watch from here is whether the Q2 numbers — and any guidance update on the generics pricing environment or the Tourette pipeline — are sufficient to narrow the persistent gap between the $41 analyst consensus and a stock that, despite a positive post-results session, remains well short of that figure.
See the live data behind this article on ORTEX.
Open TEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
